Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Health Canada authorises Roche’s PiaSky for PNH
PiaSky will be given as the first monthly subcutaneous therapy for adults and adolescents aged 13 years or more with a minimum body weight of 40kg. Patients have
PiaSky will be given as the first monthly subcutaneous therapy for adults and adolescents aged 13 years or more with a minimum body weight of 40kg. Patients have
The partnership grants Daewoong access to Salipro’s expertise and platform specifically designed for stabilising challenging membrane proteins such as G protein-coupled receptors (GPCRs), ion channels, and transporters. The
MRT-8102 is a NEK7-directed molecular glue degrader being developed to treat inflammatory diseases driven by the NLRP3 inflammasome and IL-1β. Monte Rosa Therapeutics CEO Markus Warmuth said: “The
Under the agreement, Neowise will be eligible for an upfront payment and will also receive future milestone payments. These payments are contingent upon reaching specific development, regulatory, and
Duvyzat must be administered alongside corticosteroids and is not limited by the patient’s specific genetic mutation. The decision is applicable across all 27 EU member states, as well
The alliance leverages both companies’ experience in the field of biosimilars. By combining their resources, they aim to expedite the development process while expanding the product’s availability worldwide.